Coriell to Use Affy Chips to Genotype Thousands of Volunteers; Project Will Study Effect of Genetic Risk Factors on Treatment
December 5, 2007
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) â€“ The Coriell Institute for Medical Research yesterday kicked off the Delaware Valley Personalized Medicine Project, an initiative that plans to genotype up to 100,000 patient volunteers with the goal of studying the use of genetic risk factors in patient care.
The project will use Affymetrixâ€™s Genome-Wide Human SNP Array 6.0 genotyping platform.
Coriell said the DVPMP will enroll 10,000 participants for the project over the next three years and eventually plans to reach 100,000 participants. Other partners in the program include the Fox Chase Cancer Center, Cooper University Hospital, and Virtua Health.
The initiative has so far raised $5 million from the William G. Rohrer Foundation, the William T. Read Legacy Fund, Eleanor Read, the Daniel J. Ragone Family Foundation, and Coriell's endowment.
In a statement, the DVPMP differentiated itself from â€śfor-profit personal genome companiesâ€? because it â€śaims to explore use of genetic risk factors in clinical decision-making.â€?
Under the project, participants will be encouraged to consult with their physicians about their risk variants â€śand to make important decisions about preventative care and proper medical treatments,â€? Coriell said.
All patient volunteers â€świll control access to their genetic profiles and will determine whether they wish the information to become part of their medical records in the future,â€? the institute added. There is no charge to participate.
Erin O'Shea, a professor of molecular biology at Harvard University, will chair the projectâ€™s Informed Cohort Oversight Board, which will determine which risk variants are â€śappropriateâ€? for use by patients and physicians to improve health.